

**Syngene**

Putting Science to Work

# Investor Presentation

**October 2023**



## Safe harbour



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



# Contents

|          |   |
|----------|---|
| <b>1</b> | <b>Operating Highlights</b>               |
| <b>2</b> | <b>Syngene – Putting Science to Work</b>  |
| <b>3</b> | <b>Syngene strengths</b>                  |
| <b>4</b> | <b>Financials</b>                         |
| <b>5</b> | <b>Shareholding and Share Information</b> |
|          | <b>Appendix</b>                           |



**1**

## **Operating Highlights**



# Q2 and H1 FY24 performance

## Operating Highlights

- Positive set of results for the second quarter and first half of the financial year underpinned by strong performances in Development and Manufacturing Services supported by sustained momentum in the Dedicated Centers
- In Manufacturing Services, Syngene continued to make good progress on the long-term biologics manufacturing partnership with Zoetis
- Within research services, Dedicated Centers made a steady contribution to growth and in Discovery Services, while global demand remained generally healthy, we saw the US-based biotech segment showing signs of slowed growth year-on-year as companies adjust to a new funding environment
- Commissioned a state of the art, digitally enabled Quality Control laboratory to support our growing biologics operations
- Added a new non-GMP capability center to meet market demand for agile, cost-efficient early phase development and scale-up services
- Acquisition of multi-modal facility from Stelis Biopharma Ltd, announced last quarter, is progressing
- Acquired 17 acres of non-agricultural land in Genome Valley, in Hyderabad with the aim to bolster its drug discovery capabilities
- Successfully completed the US Food and Drug Administration (US FDA) approval for the API facility in Mangalore

## Q2 Financial Highlights

Revenue from Operations growth:  
18.5% YoY  
Constant currency growth: ~15% YoY

Total Revenue: Rs 9,317 Mn  
Reported EBITDA: Rs 2,757 Mn  
Profit After Tax\*: Rs 1,220 Mn

EBITDA from operations Margin at 28%  
Profit after Tax\* Margin at 13%  
PAT\* growth at 20% YoY

## H1 Financial Highlights

Revenue from Operations growth:  
22% YoY  
Constant currency growth: ~17% YoY

Total Revenue: Rs 17,634 Mn  
Reported EBITDA: Rs 5,112 Mn  
Profit After Tax\*: Rs 2,154 Mn

EBITDA from Operations Margin at 27%  
PAT\* Margin at 12%  
PAT\* growth at 23% YoY

**Updated guidance: Revenue growth for the full year at mid-teens on a constant currency basis compared to earlier guidance of high-teen growth**

2

Syngene – Putting Science to Work



# Partner in innovation: #Putting science to work

## Who we are and what we do

*We aim to be a world class partner delivering innovative scientific solutions for clients*



*We offer integrated solutions across research, development and manufacturing*



*Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals*




*Our team includes more than ~6,000 scientists out of total ~8,500+ headcount, operating across 3 state-of-the-art campuses located in India's leading life science hubs: Bangalore, Mangalore and Hyderabad*



*Established track record in discovery research and development for small and large molecules. Emerging presence in commercial manufacturing*

# Our journey so far





# Key facts and figures



**400+**  
active clients



**13** out of top **15**  
pharma companies are  
clients



**400+**  
patents  
held with clients



**World class infrastructure**  
3 campuses in Bangalore, Hyderabad and Mangalore  
qualified to meet international standards



**Rs. 45,589 Mn**  
**(US\$567Mn\*)**  
Gross Block of  
Investments ^



**Rs. 32,638 Mn**  
**(US\$406Mn\*)**  
FY23 Revenue



**Rs. 4,644 Mn**  
**(US\$58Mn\*)**  
FY23 PAT




**~8,500+** headcount  
including ~6,000+  
talented scientists  
750 new graduate joiners



**75%**  
energy from  
renewable sources

All figures are as on March 31, 2023, unless otherwise specified. @ ca. Rs 80 /US\$

^Tangible and Intangible Assets



# Our strategic priorities



## Research: Discovery Services

Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities



## Research: Dedicated Centers

Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows



## Operational Excellence


Focus on customer delivery through operational excellence



## Development and Manufacturing Services – Small Molecules

Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions

Secure US FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects



## Development and Manufacturing Services – Large Molecules

Drive an integrated approach for biologics development and manufacturing to provide a one-stop-shop capability from drug discovery to commercial manufacturing for biologics

Accelerate capacity build-up



## People

Develop strong leaders and managers while offering all employees career-long learning opportunities



## Environmental, Social and Governance (ESG)

Committed to operating in a responsible and sustainable manner.

# Our broad capabilities, spanning the value chain, facilitate integration and captures additional benefits for clients

## Research business

### Discovery Services



**Flexible Platform** with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

**SynVent** - our proprietary platform for Integrated Drug Discovery

**SARchitect**- our proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies

### Dedicated R&D Centers



**Ring-fenced** infrastructure for exclusive operations for an individual client

**Dedicated**, multi-disciplinary team of scientists

**Access** to entire Syngene ecosystem for specialist research and development operations

## Development and Manufacturing business

### Development Services



Pre-clinical to clinical trials

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

### Manufacturing Services






Manufacturing of small and large molecules for commercial supplies




cGMP-compliant facilities

State-of-the art API manufacturing and Biologics manufacturing facilities

# Sustained investment in skilled workforce and world class infrastructure: a catalyst for expanded client base and strong revenue growth



# Strategic investments augment cash flows and EPS, driving consistent shareholder returns



# 3

## Syngene strengths



# Syngene strengths

## A global scale CRO/CDMO

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



## Solutions through innovation

- IP fully assigned to clients
- Track record of data management and security
- Over 400+ patent filings by clients recognizing Syngene scientists



## Quality matters

- Fully digitized quality organization
- Strong compliance track record with global regulators
- US FDA, EMA and PMDA approved, GLP certified, AAALAC accredited facilities
- 80 client and regulator audits in the last financial year



## Science in our DNA

- Located in 3 top India life science hubs: Bangalore, Mangalore and Hyderabad
- ~6000+ qualified scientists including ~500 PhDs (~6,000+ total headcount)
- Resilient supply chain management
- 2 Mn+ sq. ft. world-class R&D and manufacturing infrastructure



## Blue chip client list

- + 400+ active clients
- Partnering with large / mid-size / emerging biopharma and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors





## Making a difference

- Partnerships have delivered numerous clinical candidates
- Delivery history for integrated CMC programs up to clinical trials and beyond



# Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small molecules and biologics)



\* Human Pharmacology Unit




# Experienced workforce: building capabilities and careers

~8,500+  
total headcount

6000+ scientists delivering  
high quality solutions – create  
a competitive edge

■ PhDs ■ Master's Degree ■ Others



## Inspiring technical excellence and providing opportunities to grow

### Nurturing young talent and enhancing science skills

- Syngene Training Academy offers new graduate recruits a six-month extended induction to help them understand the Company's vision and values while acquiring the skills to be an industrial scientist
- Science Certification Program is open to all employees to enhance their capabilities keep their skills up to date and provide opportunities for continuous learning

### Developing leaders and managers

- Emerging Leaders Development Program is designed to help strong managers transition from managerial to leadership roles
- Manager Development Program is designed for first- and second-line managers to develop basic management skills and performance management to help them manage their teams and ensure that they are making a positive contribution to the organizational goals

### Promoting workplace diversity

- The Company has strong equal opportunity policies to protect against all forms of discrimination and provide a workplace where all employees can deliver their best work
- Support provided to parents of young families. 28% of our workforce are female and 20% of senior management positions are held by females

# Extended our State-of-the-art infrastructure & new capabilities in different locations within India to meet our strategic partners needs...

## HQ campus at Bengaluru, India

90 Acres (3,64,217 sq. mt) where most of Syngene's capabilities are housed today



### Biologics

Discovery development & manufacturing plant at HQ campus

## Fully functional R&D Centre at Genome Valley, Hyderabad, India

Genome Valley, Hyderabad, India



### API manufacturing

Commercial manufacturing to support product launch located at Mangalore, India

# We currently operate a range of successful collaboration models



## Dedicated R&D Labs

- Dedicated scientific and support personnel customized and managed to partner requirements
- Dedicated infrastructure implemented and maintained by Syngene based upon partner specifications
- Access to additional R&D, Manufacturing and support functions at Syngene
- Long-term (5-7 years) contractual commitment



## Full time equivalent (FTE)

- Dedicated scientific resources selected from partner-specified disciplines
- Deliverables and team composition evolve as project advances
- Typically ~3 year contract term ensures team continuity, adjustable with specified notice period
- Effective for longer-term research commitments



## Fee For service (FFS)

- Flexible, on-demand resources with targeted skill sets
- Clearly defined project, limited in scope and deliverables
- Effective way to managed fluctuating demand, ad-hoc requests or uncertain quantity of work



## Risk-reward

- Rewards based on clearly defined, pre-agreed milestones
- Project scope spans drug discovery, product development or truly end to end across both

... and are open to any single or combination of above

Our experience spans multiple industry segments and partners us with global leaders across the world...

Bristol Myers Squibb™

**GSK**

**sanofi**

**NOVARTIS**

**AMGEN**

**MERCK**

Boehringer  
Ingelheim

**Baxter**



Large & Mid-Sized  
BioPharma

**Albireo**  
AN IPSEN COMPANY

**AMPHISTA**  
THERAPEUTICS

**idorsia**

**Genmab**

**ASCENEURON**  
A Neurodegeneration Therapeutics Company

**PharmAust**  
LIMITED

**saniona**

**C4 Therapeutics**



Emerging  
BioPharma (EBP)

**zoetis**

**Elanco**

**MERCK**



Animal Health

**FMC**

**Dow**  
Dow AgroSciences



AgroChem

**Givaudan**

**PURINA**

**Unilever**



CPG

**BAUSCH+LOMB**

**essilor**

**Beiersdorf**

**KRATON**



Chemicals/  
Polymers

# Operational robustness driving strategy execution

## Continuous improvement embedded in operations driven by certified operational leaders

Six Sigma Black Belt certified staff in each service line and support function  
Green belt certified staff across operations  
All employees white belt certified

## Quality management system: digitized and audit-ready

80 customer and regulator audits in the last financial year  
8 successful USFDA audits in the last 4 years

## Client-focused commercial organization

Leaders based in the US, Europe, UK and Asia  
Close to client locations



## Focused execution through strong Project Management

Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects

## Digital as a differentiator

AI capability in all research teams  
IoT for maintenance and infrastructure reliability  
Data Management, IT infrastructure and security systems to strengthen our proposition as a strategic partner to clients


## Strategic Sourcing that makes a difference

Strategic supplier management to avoid supply chain disruption  
Supply distributed across the world to ensure business continuity

# We are harnessing digitization and automation through our Lab 4.0 strategy

At Syngene, we have adopted Lab 4.0, deploying technology for compliance, as an optimizer and as an augments

Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements



# Committed to safety and sustainability

## Safety is our first priority

- Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
- Risk assessments are an integral part of our operation: a proactive approach in incident prevention
- Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
- Lost time injury frequency rate (LTIFR ): 0.08



## Committed to environmental protection

- 69,280 hours of EHSS training
- 90+% of total hazardous and non-hazardous waste recycled
- 75% of energy procured from green energy sources
- 3.8% reduction in energy usage
- 2683 MT equivalent CO2 savings from energy conservation
- 52834 MT equivalent CO2 savings from green power.
- 40% freshwater savings achieved
- 71389 KL fresh water saved from recycling, reusing and rainwater harvesting.
- 1021 KL water rainwater harvested

Refer to the [CSR link](#) on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development  
Refer to the [ESG Report](#) on our website to know more

# International accreditations



- USFDA, OHSAS 18001
- GLP, cGMP, AAALAC & CPCSEA Certified facilities
- CAP accreditation, ISO/IEC 27001:2013 accreditation
- EMA and PMDA approved, AAALAC accredited facility
- The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL)





# We have consistently received industry recognition for our scientific capability and best practices

- **CMO Leadership Award Winner 2020** - under Categories: Capabilities, Compatibility, Expertise and Service
- Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia—Viral Clearance and Safety Testing'
- **Great Place to Work Certified™ Company**
- **(ASSOCHAM) CSR & NGO Awards 2020** for our contribution to COVID-19 relief work in Karnataka.
- **CMO Leadership Awards 2022** Presented by Life Science Leader and Outsourced Pharma
- **CMO Leadership Award Champion 2022** - Presented by Life Science Leader and Outsourced Pharma
- **Golden Peacock Award for Excellence in Corporate Governance** for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Unique or Innovative Leadership Program'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Advance in Compliance Training'
- **Asia Pacific Biologics CMO Excellence Awards 2022** - For Quality
- **Biopharma Honours Award 2022** - For Viral Testing Facility by Informa Markets
- **Most Preferred Workplace 2022** - Award by MarksmenDaily.com
- **Kaizen Excellence Awards:**, Won four gold awards at QCFI for s continuous improvement in finding better ways to dispense solvents safely, reducing chemical loss, eliminating contamination risks in water quality testing, and implementing green waste management practices
- **Golden Peacock Award 2023:** For risk management practices under the Pharmaceutical sector category.
- Excelled at **CII National Six Sigma Competition** winning 4 Platinum awards.
- **Brandon Hall Group Excellence Awards** in the Gold category, for learning and development



2019

2020

2021

2022

2023

H1 2024


- Ranked as one of the **25 fastest growing companies in India** by Outlook Business
- **CMO Leadership Awards 2019** - Presented by Life Science Leader Magazine
- **FICCI CSR Award for Environmental Sustainability** - At the 17th Edition of the awards in New Delhi
- **Safe Workplace Champion Award** - At the 8th Manufacturing Supply Chain Summit and Awards
- **Best Leadership Development Program for Middle Management Award** - At the 6th Global Training and Development Leadership Awards
- **India Pharma Award 2019** - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo.
- **Utthama Suraksha Puraskar 2019** - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards

- **Dream Companies to Work Award** at the 29<sup>th</sup> Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma** - for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence—Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Most Innovative New Learning Programme** at the L&D Vision & Innovation Award organized by Transformance Forums
- **Mahatma Award 2021** under Health & Wellbeing Category
- **Best Corporate Foundation Award** at the World CSR Congress

- **Golden Peacock National Quality Award 2023** For meeting the overall requirements of the Golden Peacock Excellence Model
- **Biopharma Excellence Awards 2023** For Best Contract Development and Manufacturing Organization (CDMO)

# Robust risk management framework

Syngene has a risk management framework to identify, monitor, report and manage risk  
Every risk owner monitors and manages risks relevant to their area of responsibility



Refer [Annual report](#) for complete risk profile and risk mitigation strategy

4

Financials



## Q2FY24 financial highlights

| Particulars                         | Q2 FY24      | Q2 FY23      | YoY change | Q1 FY24      | QoQ change |
|-------------------------------------|--------------|--------------|------------|--------------|------------|
| <b>Revenue from operations</b>      | <b>9,101</b> | <b>7,681</b> | <b>18%</b> | <b>8,081</b> | <b>13%</b> |
| Other income                        | 216          | 154          | 40%        | 236          | -8%        |
| <b>Reported revenue</b>             | <b>9,317</b> | <b>7,835</b> | <b>19%</b> | <b>8,317</b> | <b>12%</b> |
| Material costs                      | 2,672        | 1,990        | 34%        | 2,228        | 20%        |
| Staff costs                         | 2,412        | 2,185        | 10%        | 2,288        | 5%         |
| Other direct costs                  | 275          | 288          | -4%        | 275          | 0%         |
| Other expenses                      | 1,022        | 867          | 18%        | 1,016        | 1%         |
| Foreign exchange (gain)/loss, net   | 179          | 186          | -4%        | 155          | 16%        |
| <b>EBITDA</b>                       | <b>2,757</b> | <b>2,319</b> | <b>19%</b> | <b>2,355</b> | <b>17%</b> |
| <b>EBITDA Margin</b>                | <b>29.6%</b> | <b>29.6%</b> |            | <b>28.3%</b> |            |
| Depreciation and Finance Cost       | 1,176        | 1,019        | 15%        | 1,126        | 4%         |
| <b>PBT</b>                          | <b>1,581</b> | <b>1,300</b> | <b>22%</b> | <b>1,229</b> | <b>29%</b> |
| Tax                                 | 361          | 280          | 29%        | 295          | 22%        |
| <b>PAT before exceptional items</b> | <b>1,220</b> | <b>1,020</b> | <b>20%</b> | <b>934</b>   | <b>31%</b> |
| PAT Margin                          | 13.1%        | 13.0%        |            | 11.2%        |            |
| <b>PAT after exceptional items*</b> | <b>1,167</b> | <b>1,020</b> | <b>14%</b> | <b>934</b>   | <b>25%</b> |

All figures in Rs. Mn unless otherwise specified

## Balance Sheet Highlights

As on 30th September 2023

|                                 |               |
|---------------------------------|---------------|
| Shareholders' funds             | 38,909        |
| Net Fixed assets                | 29,871        |
| Other net assets <sup>(1)</sup> | -369          |
| Net cash/(debt) <sup>(2)</sup>  | 9,407         |
| <b>Total Use of Funds</b>       | <b>38,909</b> |

# H1FY24 financial highlights

| Particulars                         | H1 FY24 | H1 FY23 | Y-o-Y change |
|-------------------------------------|---------|---------|--------------|
| <b>Revenue from operations</b>      | 17,182  | 14,125  | 22%          |
| Other income                        | 452     | 309     | 46%          |
| <b>Reported revenue</b>             | 17,634  | 14,435  | 22%          |
| Material costs                      | 4,900   | 3,602   | 36%          |
| Staff costs                         | 4,701   | 4,155   | 13%          |
| Other direct costs                  | 551     | 571     | -4%          |
| Other expenses                      | 2,036   | 1,685   | 21%          |
| Foreign exchange (gain)/loss, net   | 334     | 220     | 52%          |
| <b>EBITDA</b>                       | 5,112   | 4,202   | 22%          |
| <b>EBITDA Margin</b>                | 29%     | 29%     |              |
| Depreciation and Finance Cost       | 2,302   | 1,975   | 17%          |
| <b>PBT</b>                          | 2,810   | 2,227   | 26%          |
| Tax                                 | 656     | 469     | 40%          |
| <b>PAT before exceptional items</b> | 2,154   | 1,759   | 23%          |
| PAT Margin                          | 12.2%   | 12.2%   |              |
| <b>PAT after exceptional items*</b> | 2,101   | 1,759   | 19%          |

All figures in Rs. Mn unless otherwise specified

# 5

## Shareholding and Share Information



# Syngene and Biocon Group

## Syngene

**Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. Company has 25+ years of experience in novel molecule discovery, development and manufacturing services**




**Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene**

**Syngene**

### **Integrated services:**

- Discovery research
- Development
- Manufacturing small/large molecules




- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs



# Shareholding and Share Information

## Syngene's Shareholding Pattern\*



## Syngene's Share Information\*

|                                |          |
|--------------------------------|----------|
| NSE Ticker                     | SYNGENE  |
| BSE Ticker                     | 539268   |
| Market Cap (Rs. Mn)            | 3,23,280 |
| % free-float                   | 44%      |
| Free-float market cap (Rs. Mn) | 1,42,243 |
| Share Outstanding (Mn)         | 402      |



## For more details

Visit our website [www.syngeneintl.com](http://www.syngeneintl.com)



<https://twitter.com/SyngeneIntl>



<https://www.linkedin.com/company/syngene-international-limited>



<https://www.facebook.com/syngeneintl/>



<https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ>

IR Contact:

**Krishnan G/ Suruchi Daga**

+ 91 9819992927/+91 8800176009

[investor@syngeneintl.com](mailto:investor@syngeneintl.com)

[krishnan.g@syngeneintl.com](mailto:krishnan.g@syngeneintl.com)

[suruchi.daga@syngeneintl.com](mailto:suruchi.daga@syngeneintl.com)

Media Contact:

**Shotorupa Ghosh**

+91 8450977080

[shotorupa.ghosh@syngeneintl.com](mailto:shotorupa.ghosh@syngeneintl.com)



# Syngene

Putting Science to Work

# Thank you

© 2023 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document.

[www.syngeneintl.com](http://www.syngeneintl.com)

Stay Connected

